Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

By M. Brousseau, E. Schaefer, M. Wolfe, L. Bloedon, A. Digenio, R. Clark, J. Mancuso, D. Rader. New England Journal of Medicine, 2004

795 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/31fb6fd6f4daa51e0ee136a61ccc7042573a5052

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. J. Chapman
2. A. Kontush

In Surgery

1. J. Chapman
2. A. Kontush

Citations in the corpus

• Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis (2006, background): “In subjects with low levels of HDL-C, treatment with 120 and 240 mg of torcetrapib daily raised plasma HDL-C concentrations by 46 and 106%, respectively (Brousseau et al., 2004).”